Clinical Trial

Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This study is a large-scale, prospective, multi-center, and non-interventional observation study to observe blood pressure and blood lipid changes and safety during administration of olomax tablets for 24 weeks in hypertensive patients with dyslipidemia.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-12-13; most recent amendment 2025-08-22.
Status change: Recruiting → Active, Not Recruiting 2024-07-01
Trial Details
NCT Number NCT05660135
Lead Sponsor Daewoong Pharmaceutical Co. LTD.
Conditions Hypertension, Dyslipidemias
Enrollment 4,000 participants
Start Date 2022-06-20
Primary Completion 2024-11-30 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-24